Kisa
|
346a1fb58e
|
feat: Signal CGM strategic analysis + asset sale package
Adds complete go-to-market analysis for Signal CGM asset sale:
Analysis/
- signal-cgm-segment-scoring-v1.md (3-model scoring across 7 segments)
- signal-cgm-re-scored-composite-v2.md (50/30/20 composite, MA+Medicaid scope)
- signal-cgm-final-ranking-leverage-v3.md (final 4-segment rank + leverage map)
Assets/
- signal-cgm-pitch-v1-plain.md (plain language leave-behind)
- signal-cgm-pitch-v2-professional.md (professional leave-behind)
- master-summary.md (rankings, metrics, next-steps prompt)
Key findings: 25.2% CGM improper payment rate; 20% net revenue loss;
63% of denied claims permanently written off; billing company #1 target
for pilot; NikoHealth #1 for asset sale.
Co-Authored-By: Claude Sonnet 4.6 <noreply@anthropic.com>
|
2026-04-19 20:37:18 -04:00 |
|